142 related articles for article (PubMed ID: 9842645)
1. Overexpression of MDM2 in acute childhood lymphoblastic leukemia.
Gustafsson B; Stål O; Gustafsson B
Pediatr Hematol Oncol; 1998; 15(6):519-26. PubMed ID: 9842645
[TBL] [Abstract][Full Text] [Related]
2. High incidence of potential p53 inactivation in poor outcome childhood acute lymphoblastic leukemia at diagnosis.
Marks DI; Kurz BW; Link MP; Ng E; Shuster JJ; Lauer SJ; Brodsky I; Haines DS
Blood; 1996 Feb; 87(3):1155-61. PubMed ID: 8562942
[TBL] [Abstract][Full Text] [Related]
3. MDM2 and p53 in childhood acute lymphoblastic leukemia: higher expression in childhood leukemias with poor prognosis compared to long-term survivors.
Gustafsson B; Axelsson B; Gustafsson B; Christensson B; Winiarski J
Pediatr Hematol Oncol; 2001 Dec; 18(8):497-508. PubMed ID: 11764099
[TBL] [Abstract][Full Text] [Related]
4. Incidence and prognostic significance of MDM2 oncoprotein overexpression in relapsed childhood acute lymphoblastic leukemia.
Zhou M; Gu L; Abshire TC; Homans A; Billett AL; Yeager AM; Findley HW
Leukemia; 2000 Jan; 14(1):61-7. PubMed ID: 10637478
[TBL] [Abstract][Full Text] [Related]
5. Cellular expression of MDM2 and p53 in childhood leukemias with poor prognosis.
Gustafsson B; Christenson B; Hjalmar V; Winiarski J
Med Pediatr Oncol; 2000 Feb; 34(2):117-24. PubMed ID: 10657873
[TBL] [Abstract][Full Text] [Related]
6. Frequency and prognostic significance of murine double minute protein-2 overexpression and p53 gene mutations in childhood acute lymphoblastic leukemia.
Hendy OM; Elghannam DM; El-Sharnouby JA; Goda EF; El-Ashry R; Al-Tonbary Y
Hematology; 2009 Dec; 14(6):335-40. PubMed ID: 19941740
[TBL] [Abstract][Full Text] [Related]
7. [Involvement of WT1 gene expression in regulation of P53 and MDM2 proteins function in acute lymphoblastic leukemia].
Bartkowiak J; Wójcik I; Stankiewicz W
Pol Merkur Lekarski; 2001 Nov; 11(65):402-5. PubMed ID: 11852808
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of the MDM2 gene by childhood acute lymphoblastic leukemia cells expressing the wild-type p53 gene.
Zhou M; Yeager AM; Smith SD; Findley HW
Blood; 1995 Mar; 85(6):1608-14. PubMed ID: 7888679
[TBL] [Abstract][Full Text] [Related]
9. MDM2 gene amplification and expression in non-small-cell lung cancer: immunohistochemical expression of its protein is a favourable prognostic marker in patients without p53 protein accumulation.
Higashiyama M; Doi O; Kodama K; Yokouchi H; Kasugai T; Ishiguro S; Takami K; Nakayama T; Nishisho I
Br J Cancer; 1997; 75(9):1302-8. PubMed ID: 9155050
[TBL] [Abstract][Full Text] [Related]
10. Prevalence and prognostic significance of murine double minute protein-2 overexpression and P53 gene mutations in childhood acute lymphoblastic leukemia.
Hendy OM; Elghannam DM; El-Sharnouby JA; Goda EF; El-Ashry R; Al-Tonbary Y
Egypt J Immunol; 2008; 15(1):93-100. PubMed ID: 20306673
[TBL] [Abstract][Full Text] [Related]
11. Altered expression of p53 and mdm-2 proteins at diagnosis is associated with early treatment failure in childhood acute lymphoblastic leukemia.
Marks DI; Kurz BW; Link MP; Ng E; Shuster JJ; Lauer SJ; Carroll D; Brodsky I; Haines DS
J Clin Oncol; 1997 Mar; 15(3):1158-62. PubMed ID: 9060559
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of the MDM2 oncogene in leukemia and lymphoma.
Watanabe T; Ichikawa A; Saito H; Hotta T
Leuk Lymphoma; 1996 May; 21(5-6):391-7, color plates XVI following 5. PubMed ID: 9172803
[TBL] [Abstract][Full Text] [Related]
13. MDM2 overexpression does not account for stabilization of wild-type p53 protein in non-Hodgkin's lymphomas.
Maestro R; Gloghini A; Doglioni C; Gasparotto D; Vukosavljevic T; De Re V; Laurino L; Carbone A; Boiocchi M
Blood; 1995 Jun; 85(11):3239-46. PubMed ID: 7756655
[TBL] [Abstract][Full Text] [Related]
14. [Study on MDM2 and p53 gene proteins expression on acute leukemic cells and its correlation with chemotherapeutic efficacy].
Lin M; Liu Y; Jin J
Zhonghua Xue Ye Xue Za Zhi; 1998 Jul; 19(7):350-2. PubMed ID: 11189516
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of MDM2, due to enhanced translation, results in inactivation of wild-type p53 in Burkitt's lymphoma cells.
Capoulade C; Bressac-de Paillerets B; Lefrère I; Ronsin M; Feunteun J; Tursz T; Wiels J
Oncogene; 1998 Mar; 16(12):1603-10. PubMed ID: 9569028
[TBL] [Abstract][Full Text] [Related]
16. P53 mutation and MDM2 amplification frequency in pediatric rhabdomyosarcoma tumors and cell lines.
Taylor AC; Shu L; Danks MK; Poquette CA; Shetty S; Thayer MJ; Houghton PJ; Harris LC
Med Pediatr Oncol; 2000 Aug; 35(2):96-103. PubMed ID: 10918230
[TBL] [Abstract][Full Text] [Related]
17. Abnormalities of the P53, MDM2, BCL2 and BAX genes in acute leukemias.
Wojcik I; Szybka M; Golanska E; Rieske P; Blonski JZ; Robak T; Bartkowiak J
Neoplasma; 2005; 52(4):318-24. PubMed ID: 16059649
[TBL] [Abstract][Full Text] [Related]
18. Strong correlation of basement membrane degradation with p53 inactivation and/or MDM2 overexpression in superficial urothelial carcinomas.
Ozdemir E; Kakehi Y; Okuno H; Habuchi T; Okada Y; Yoshida O
J Urol; 1997 Jul; 158(1):206-11. PubMed ID: 9186361
[TBL] [Abstract][Full Text] [Related]
19. [Role of functional inactivation of p53 from MDM2 overexpression in hepatocarcinogenesis].
Luo YL; Cheng RX; Feng DY
Hunan Yi Ke Da Xue Xue Bao; 2001 Feb; 26(1):13-6. PubMed ID: 12536604
[TBL] [Abstract][Full Text] [Related]
20. [TP53 gene aberrations in chondromatous neoplasms: correlation with immunohistochemical p53 accumulation and MDM2 expression].
Blasenbreu S; Baretton GB; Bender C; Haas CJ; Diebold J; Löhrs U
Verh Dtsch Ges Pathol; 1998; 82():284-9. PubMed ID: 10095448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
